Article Text
PDFCommentary
Moral obligation to actively reinterpret VUS and the constraint of NGS technologies
Statistics from Altmetric.com
Footnotes
Twitter @DrVic_Exotic
Contributors I am the sole author of this article.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
Read the full text or download the PDF:
Other content recommended for you
- Is there a duty to routinely reinterpret genomic variant classifications?
- Optimising clinical care through CDH1-specific germline variant curation: improvement of clinical assertions and updated curation guidelines
- The UCL low-density lipoprotein receptor gene variant database: pathogenicity update
- Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort
- Variant reclassification and clinical implications
- Clinical implications of VUS reclassification in a single-centre series from application of ACMG/AMP classification rules specified for BRCA1/2
- Modern genomic techniques in the identification of genetic causes of cardiomyopathy
- Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel
- International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma
- Genomics for paediatricians: promises and pitfalls